Icon
+91 94997 68112
Login Register

OMCAZIO - (EQ 11.5MG BASE, EQ 23MG BASE, EQ 34.5MG BASE; CAPSULE)

CABOZANTINIB LAURYLSULFATE HANDA ONCOL
EQ 11.5MG BASE, EQ 23MG BASE, EQ 34.5MG BASE; CAPSULE
Less Than $1000 mn
None None
None None
None None
OMCAZIO is a kinase inhibitor indicated for the treatment of • patients with advanced renal cell carcinoma (RCC). • patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab. • patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. • adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
Yes
OMCAZIO Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.